Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/world/chinas-cansino-in-talks-for-covid-19-vaccine-phase-iii-trial-overseas-312714" hreflang="en">China's Cansino in talks for COVID-19 vaccine phase III trial overseas</a>

"Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus," Tarasov said.

The university began the trials on June 18 and the vaccines were produced by Russia's Gamalei Institute of Epidemiology and Microbiology.

Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University, said that the main objective of this stage of the study was to show the vaccine's safety for human health, which was successfully done.

"The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market," Lukashev told Sputnik.

According to Lukashev, further development plan for the vaccine is already determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production.&nbsp;

"Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drugs ... We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway," Tarasov noted.&nbsp;

Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20.

Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20. Also read: China's Cansino in talks for COVID-19 vaccine phase III trial overseas "Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus," Tarasov said. The university began the trials on June 18 and the vaccines were produced by Russia's Gamalei Institute of Epidemiology and Microbiology. Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University, said that the main objective of this stage of the study was to show the vaccine's safety for human health, which was successfully done. "The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market," Lukashev told Sputnik. According to Lukashev, further development plan for the vaccine is already determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production. "Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drugs ... We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway," Tarasov noted.

Russia's Sechenov University completes trials of world's first COVID-19 vaccine

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year.&nbsp;

According to biotechnology company's research chief Dr Gregory Glenn, Novavax has commenced the first phase of the trial in which 131 volunteers will be tested. These volunteers will be from the cities of Melbourne and Brisbane and the test will look for early signs of the vaccine’s effectiveness.&nbsp;

“We are in parallel making doses, making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year,” Glenn told a virtual press conference in Melbourne from Novavax’ headquarters in Maryland.

Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed.&nbsp;

Most of the 'tested' vaccines aim to train the immunity system so that it recognizes the spike in the protein that studs the coronavirus' outer surface, instructing the body to react if it ever encountered the real infection. While other companies are making vaccines that are made using just the genetic code for that protein, and others use a harmless virus to deliver the protein-producing information. Still, other vaccine candidates are more old-fashioned, made with the killed whole virus.

Novavax has made another addition to the list of 'types of vaccines'. They have introduced the 'recombinant vaccine'. In these vaccines, Novavax has used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year.

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year. According to biotechnology company's research chief Dr Gregory Glenn, Novavax has commenced the first phase of the trial in which 131 volunteers will be tested. These volunteers will be from the cities of Melbourne and Brisbane and the test will look for early signs of the vaccine’s effectiveness. “We are in parallel making doses, making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year,” Glenn told a virtual press conference in Melbourne from Novavax’ headquarters in Maryland. Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed. Most of the 'tested' vaccines aim to train the immunity system so that it recognizes the spike in the protein that studs the coronavirus' outer surface, instructing the body to react if it ever encountered the real infection. While other companies are making vaccines that are made using just the genetic code for that protein, and others use a harmless virus to deliver the protein-producing information. Still, other vaccine candidates are more old-fashioned, made with the killed whole virus. Novavax has made another addition to the list of 'types of vaccines'. They have introduced the 'recombinant vaccine'. In these vaccines, Novavax has used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.

US company Novavax to conduct human trials of 'recombinant vaccine' in Australia

From a verbal threat to an official warning, the US has alleged China of launching cyber attacks to steal its Covid-19 vaccine research.

Is China stealing US vaccine research?

covid-vaccine

Covid Vaccine, News on Covid Vaccine, stories on Covid Vaccine, articles on Covid Vaccine, Covid Vaccine stories at Wion, Covid Vaccine news, Covid Vaccine latest news

covid vaccine

Russia's Sechenov University completes trials of world's first COVID-19 vaccine

US company Novavax to conduct human trials of 'recombinant vaccine' in Australia

Is China stealing US vaccine research?